Fetzima (levomilnacipran) is a prescription drug used to treat major depressive disorder (also called depression) in adults. Fetzima can cause side effects that range from mild to serious. Examples ...

Fetzima (levomilnacipran) is prescribed to treat depression. The drug comes as an extended-release capsule. That means the drug releases into your body slowly over some time. You usually swallow it ...

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE:FRX) announced today that FETZIMA™ (levomilnacipran ER capsules), is now available in pharmacies throughout the United States. FETZIMA was ...

New Depression Drug Gets Green Light from FDA Forest Laboratories announced that Fetzima (levomilnacipran extended-release) capsules are now available. Fetzima is a potent and selective serotonin and ...

NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) and Pierre Fabre Laboratories announced today that FETZIMA™ (levomilnacipran extended-release capsules), a once-daily ...

Major Depressive Disorder, also known as depression, is a common debilitating disorder in which feelings of sadness and other symptoms interfere with a person's ability to work, sleep, study, eat, and ...

Forest Laboratories Inc. FRX and Pierre Fabre Laboratories on Friday said their treatment for depression was approved by the U.S. Food and Drug Administration. Fetzima is a once-daily serotonin and ...

Forest (FRX) hopes its new depression drugs will recapture market share lost when its $2 billion a year Lexapro went off-patent in 2012. In anticipation of the patent expiration for its best selling ...

Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIMA™ for the Treatment of Major Depressive Disorder in Adults NEW YORK & CASTRES, France--(BUSINESS WIRE)--Forest ...

ADDING MULTIMEDIA: Forest Laboratories and Pierre Fabre Laboratories Announce FDA Approval of FETZIMA™ for the Treatment of Major Depressive Disorder in Adults NEW YORK & CASTRES, France-- (BUSINESS ...